Biogen announced that the Board of Directors has elected Caroline Dorsa as Chair of the Board of Directors, effective immediately following the Company’s 2023 Annual Meeting of Stockholders, scheduled to take place on June 14, 2023. Dorsa will succeed Stelios Papadopoulos, Ph.D., who announced he would not stand for reelection to the Board at the Annual Meeting. Dorsa joined the Biogen Board in 2010.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BIIB:
- Caroline Dorsa to Succeed Stelios Papadopoulos as Chair of Biogen Board of Directors
- Biogen, Sage Therapeutics: FDA has no plans to discuss NDA for zuranolone
- Eisai, Biogen say FDA accepted sBLA for LEQEMBI, granted Priority Review
- FDA Accepts Eisai’s Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
- Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration